The use of a neutralizing anti TNFa Antibody, High affinity, in the manufacture of a Drug and a set of elements

摘要

1. The use of a neutralizing antibody against TNFa, which is closely related to the development of a drug for the treatment of TNFa disorders, and includes a series of pharmaceutical components containing this anti TNFa antibody. 1. Characteristic 1: a method for treating TNFa related disorders in experimental subjects. In the experimental subjects, TNFa related disorders are selected from a group of people including sporozoites, pulmonary disorders, coronary artery disorders, metabolic disorders, anemia, pain, liver disorders, and skin disorders, A disorder or vasculitis of the nailscharacterized in that it comprises administering to the subject an effective amount for therapeutic use of a neutralizing anti-TNFa antibody, of great affinity, whereby said TNFa-related disorder is managed. Claim 4: The method of any of clauses 1, 2 or 3, characterized in that the antibody is an isolated human antibody, or a portion thereof that binds to the antigen, which dissociates from human TNFa with a Kᵈ of 1 x 10 ⁻⁸ M ᵒ ᵐᵉⁿᵒˢ ʸ ᵘⁿᵃ ᶜᵒⁿˢᵗᵃⁿᵗᵉ ᵈᵉ ᵛᵉˡᵒᶜⁱᵈᵃᵈ Kₒᶠᶠ of 1 x 10⁻³ s⁻¹ or less, both determined by surface plasmon resonance,and that neutralizes the cytotoxicity of human TNFa in a standard in vitro L929 assay with an IC₅₀ of 1 X 10⁻⁷ M ᵒ ᵐᵉⁿᵒˢ. Claim 15: A set of elements, characterized in that it comprises: a) a pharmaceutical composition comprising an anti-TNFa antibody, or a portion that binds to the antigen thereof, and a vehicle acceptable for pharmaceutical use; and b) instructions for administration to the subject of the pharmaceutical composition with the anti-TNFa antibody to treat a subject suffering from a TNFa-related disorder.